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Abstract
Background Co-formulated elvitegravir, cobicistat,
emtricitabine, and tenofovir disoproxil fumarate (EVG/
COBI/FTC/TDF; Stribild) is a guideline-recommended
regimen for HIV treatment-naı¨ve patients and a switch
option for virologically suppressed patients.
Objective The purpose of this analysis was to understand
how HIV patients’ symptoms change after switching to
Stribild versus continuing a regimen consisting of a non-
nucleoside reverse transcriptase inhibitor (NNRTI) with
emtricitabine and tenofovir disoproxil fumarate.
Methods A secondary analysis was conducted of the
STRATEGY-NNRTI study (GS-US-236-0121), a ran-
domized, open-label, phase IIIb trial of HIV-infected adults
who were taking an NNRTI plus FTC/TDF and were ran-
domly assigned (2:1) either to Stribild (‘switch’) or to
continue on their existing regimen (‘no-switch’). Logistic
regressions and longitudinal modeling were conducted to
evaluate the relationship of treatment with bothersome
symptoms. These models adjusted for age, sex, race,
number of bothersome symptoms at baseline, Veterans
Aging Cohort Study Risk (VACS) Index score, years since
HIV diagnosis, and first antiretroviral therapy use, NNRTI
type, serious mental illness, and baseline depression and
health-related quality of life (HRQL) scores.
Results At baseline, the prevalence of nightmares, vivid
dreams, weird/intense dreams, muscle aches/joint pain, and
fevers/chills/sweats was greater in the switch group. The
prevalence of nightmare, vivid dreams, weird/intense
dreams, dizzy/lightheadedness, fatigue/loss of energy, and
pain/numbness/tingling in hands/feet deceased in the switch
group at week 4, and these benefits were maintained over
time. Nervous/anxious, drowsiness, trouble remembering,
off balance, and body changes decreased in the switch
group at week 4 but were not maintained over time. Diffi-
culty sleeping, diarrhea/loose bowels, and bloating did not
differ in prevalence at week 4 or 48, but longitudinal models
suggested differences between groups over time. HRQL did
not differ between groups and was unchanged over time.
Conclusions In this study sample, a switch to co-formu-
lated EVG/COBI/FTC/TDF was associated with significant
persistent improvements in six patient-reported HIV
symptoms.
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Key Points for Decision Makers
Little is known about how HIV patients’ symptoms
change after switching to Stribild versus continuing
a regimen consisting of a non-nucleoside reverse
transcriptase inhibitor (NNRTI) with emtricitabine
and tenofovir disoproxil fumarate.
In this study, switching to Stribild was associated
with significant persistent improvements from
baseline to 48 weeks in six patient-reported HIV
symptoms: nightmares, vivid dreams, weird/intense
dreams, dizzy/lightheadedness, fatigue/loss of
energy, and pain/numbness/tingling in hands/feet.
Higher levels of satisfaction with treatment were
evident in patients who switched to Stribild
compared with the no-switch group at the first
follow-up visit and subsequent measurement time
point.
1 Introduction
Effective management of HIV-associated symptoms and
antiretroviral (ARV)-associated adverse effects can
improve health-related quality of life (HRQL) [1–3]. In
addition, well-tolerated therapies improve treatment
adherence and persistence [4–6]. Given current therapies
have extended HIV survival [7], improving patients’ daily
lives by minimizing and managing symptoms is of con-
siderable importance [8].
One approach to improve drug-associated side effects
and tolerability in virologically suppressed patients is to
switch ARV therapy. Single-tablet regimens can be an
attractive switch option because of their inherent conve-
nience. The co-formulated regimen of elvitegravir,
cobicistat, emtricitabine, and tenofovir disoproxil fumarate
(EVG/COBI/FTC/TDF; Stribild [STB]) is indicated as a
switch option for virologically suppressed HIV-infected
adults taking a non-nucleoside reverse transcriptase inhi-
bitor (NNRTI) with FTC and TDF [9, 10]. Patients on an
NNRTI-containing regimen might be appropriate candi-
dates for treatment modification to an NNRTI-sparing
regimen like STB if they have bothersome neuropsychi-
atric side effects such as anxiety, insomnia, dizziness, and
abnormal dreams [11]. Other commonly recognized
symptoms associated with contemporary NNRTI-contain-
ing regimens include skin reactions, fever, fatigue, hand/-
foot pain, nausea/vomiting, diarrhea, and headaches [12].
The patient symptom experience after switching to a
treatment like STB may inform or predict treatment
adherence, persistence, quality of life, and/or treatment
satisfaction; however, these associations are rarely exam-
ined in large randomized clinical trials evaluating HIV
therapies [13, 14]. Therefore, the purpose of this secondary
analysis was to evaluate the patient HIV symptom expe-
rience and HRQL over 48 weeks among those who swit-
ched to STB as compared with those who continued their
NNRTI plus FTC/TDF regimen.
2 Methods
2.1 Study Design
The study design and patient recruitment have been pre-
viously described [10] but are summarized here. STRAT-
EGY-NNRTI was an international, open-label, randomized
study to evaluate the efficacy (non-inferiority), safety, and
tolerability of switching to the single-tablet regimen STB,
containing EVG 150 mg, COBI 150 mg, FTC 200 mg, and
TDF 300 mg, from a regimen consisting of an NNRTI plus
FTC/TDF (NNRTI ? FTC/TDF) in virologically sup-
pressed HIV-1 infected adults. A total of 439 participants
were randomly assigned (2:1) and dosed; 292 switched to
STB (‘switch’ group) and 147 continued on their baseline
NNRTI-containing regimen (‘no-switch’ group). After
exclusions, 291 and 143 participants, respectively, were
analyzed in the modified intention-to-treat population.
Post-baseline study visits occurred at weeks 4, 8, 12, 24,
36, and 48. The study design was open-label; participants
and investigators were not masked to group allocation.
2.2 Baseline Demographics and Clinical
Characteristics
Demographics (sex, age, race, ethnicity) and clinical
characteristics (serious mental illness, CD4 cell count,
asymptomatic status, years since HIV diagnosis, years
since first ARV therapy use, on first ARV regimen, and
NNRTI at randomization) were collected. Serious mental
illness was defined as having a diagnosis of one or more of
the following conditions based on medical chart review:
major depression, anxiety, schizophrenia, bipolar disorder,
post-traumatic stress disorder, or other psychosis.
The Veterans Aging Cohort Study Risk (VACS) Index
was calculated to quantify the overall mortality risk asso-
ciated with HIV. The VACS Index is a summary score
based on age, CD4 count, HIV-1 RNA, the Fibrosis (FIB)-4
score, creatinine, and viral hepatitis C infection to predict
all-cause and cause-specific mortality and other outcomes
in those living with HIV infection and mortality among
360 A. Mills et al.
those without HIV infection [15, 16]. The FIB-4 score,
computed using age, platelets, and aspartate and alanine
transaminase values provides an estimate of the degree of
liver fibrosis in HIV and hepatitis C virus co-infected
patients [17].
2.3 Patient-Reported Outcomes (PROs)
2.3.1 Dependent Variables
Patient-reported outcomes (PROs) used as dependent
variables in this secondary data analysis included the
following.
2.3.1.1 Modified HIV Symptom Index (HIV-SI) A modi-
fied version of the HIV Symptom Index (HIV-SI) was used
to evaluate symptom-specific bother. The HIV-SI [16],
which was developed to assess 20 commonly experienced
symptoms based on literature review and clinical and
advisory board feedback, is supported by evidence of good
construct validity and has been considered the gold stan-
dard in contemporary HIV symptom research [3]. Patients
are asked about their experience of each of the symptoms
during the past 4 weeks on a five-point Likert scale.
Response options and scores are as follows: (0) ‘‘I don’t
have this symptom’’; (1) ‘‘I have this symptom and it
doesn’t bother me’’; (2) ‘‘I have this symptom and it
bothers me a little’’; (3) ‘‘I have this symptom and it
bothers me’’; (4) ‘‘I have this symptom and it bothers me a
lot’’.
Modifications to the instrument included the following.
The question ‘‘Nausea or vomiting?’’ was separated into
two discrete questions (‘‘Nausea?’’ and ‘‘Vomiting?’’) to
distinguish the difference in these symptoms, as nausea is
more common than vomiting in patients taking multiple
HIV medications. The question ‘‘Felt sad, down or
depressed?’’ was removed and substituted with a more
specific questionnaire on depression—the Center for Epi-
demiological Studies—Depression (CES-D; described
below). In order to identify changes in drug-associated
neuropsychiatric symptoms, which have been well descri-
bed in relation to efavirenz [11], additional symptoms as
identified in the US prescribing information for efavirenz
(Sustiva) were added to the instrument for the present
study. Six questions were added to assess symptoms of
dreams (‘‘Nightmare?’’, ‘‘Vivid dreams?’’, and ‘‘Weird or
intense dreams?’’) and balance (‘‘Feeling off balance?’’,
‘‘Felt drowsy?’’, and ‘‘Unsteady walking?’’).
Consistent with prior analyses by Edelman et al. [13],
symptoms were dichotomized as bothersome (2, 3, or 4)
versus not bothersome (0, 1) in order to provide information
about symptoms not just present but bothersome, and thus
clinically relevant to treatment decisions. In addition, the
overall bothersome symptom count at baseline was gener-
ated by counting the number of individual symptoms scored
as ‘bothered’ and used as a covariate in regression analyses
and longitudinal modeling of baseline to week 48 data.
2.3.1.2 Short Form-36 (SF-36) The physical component
summary (PCS) and mental component summary (MCS)
from the Short-Form (SF)-36 were used to evaluate HRQL
[18]. The SF-36 is supported by extensive evidence of good
psychometric properties in a range of therapeutic areas
[19]. Scores for the PCS and MCS range from 0 to 100,
with higher scores representing better HRQL.
2.3.2 Descriptive Measures
PROs used to provide descriptive information and as
covariates in regression and longitudinal analyses of base-
line to week 48 data included the following: (1) the CES-D,
a 20-item instrument used to measure depressive symp-
tomatology and supported by evidence of reliability and
validity in HIV clinical trials [3, 20]; (2) the State Trait
Anxiety Inventory (STAI), a 40-item measure that assesses
trait and state anxiety and has demonstrated good psycho-
metric properties in a range of therapeutic areas [21]; (3) the
Visual Analog Scale (VAS) Adherence Questionnaire [22],
a validated instrument that correlates significantly with
Medication Event Monitoring System caps and pharmacy
data, used to assess patient-reported adherence to their ARV
regimen using a linear scale (0–100 %) to indicate the
percentage of medication taken in the last 30 days; (4) and
the HIV Treatment Satisfaction Questionnaire (HIVTSQ), a
10-item instrument with five items assessing general treat-
ment satisfaction and five items assessing treatment ease
[23] that is supported by evidence of good internal consis-
tency reliability [24]. The Status form (HIVTSQs) was used
at baseline and asks about ‘‘now’’, and the change form
(HIVTSQc), in which items state ‘‘compared to before’’, was
used at week 4 and week 24. The response options for the
HIVTSQs form are anchored at 6 and 0, and those for the
HIVTSQc form range from values of 3 to -3. The total
score ranges from 0 to 60 for the status form and from -30
to 30 for the change form, with higher positive scores
indicating more/improved satisfaction and higher negative
scores indicating greater dissatisfaction.
2.4 Statistical Analysis
Analyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC, USA). Questionnaires were submitted
by 98 % of enrolled patients at baseline and by 90 % at
week 48; the decline was partly due to patients who left the
study. Of questionnaires received, roughly 300 items had
missing values, of a total of 340,000 records (\0.1 %).
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Following recommendations from the instrument developer,
Amy Justice (Professor of Medicine and Public Health—
Yale School of Medicine), the following imputation rules
were applied to the HIV-SI data. If multiple responses were
provided for a single item, the most severe (maximum) of
the responses was used. Where single items were left blank,
yet other items were completed, the missing value was
imputed to ‘‘I do not have this symptom’’, a score of 0.
Descriptive statistics were used to characterize the
sample at baseline, including demographic and clinical
characteristics and PROs. Unadjusted and adjusted analy-
ses at week 4 and week 48 were completed to evaluate the
relationship of treatment with the probability of experi-
encing HIV-SI items and physical and mental HRQL as
evaluated by the SF-36 PCS and MCS, respectively.
Consistent with prior work by Edelman et al. [13], HIV-SI
items were modeled as binary outcomes using a logistic
regression model analysis, and the PCS and MCS were
modeled using general linear regression models. Each
model included treatment as the independent variable and
covariates that were selected from a number of potential
variables that were evaluated for multicollinearity.
Furthermore, generalized linear mixed-model regres-
sions were conducted to evaluate changes in the prevalence
of each of the HIV symptoms over 48 weeks. The func-
tional form of the change pattern was assessed visually
from the observed prevalence in each group. Linear and
quadratic patterns were tested to determine optimal fit,
ultimately favoring a linear function. Given the open-label
nature of the study and the potential for a response bias, we
decided to model weeks 4 through 48 and include baseline
as a covariate. To assess the possibility that the effect of
treatment may itself vary over time, the models included an
interaction between treatment and time in addition to the
indicator of treatment group. Continuous variables were
mean centered for ease of interpretation and model fit. No
model reduction was performed; all predictors were
retained in each model. The fit of the derived models was
compared with a simple unadjusted model that included
time and treatment along with a random intercept to
account for the longitudinal nature of the data. The com-
parison was based on Bayesian information criterion (BIC).
A similar modeling approach was used to model the
changes over time in the SF-36 PCS and MCS, which used
a linear mixed-model regression.
3 Results
3.1 Baseline Characteristics
Baseline demographics and clinical characteristics were
similar in the two treatment groups (Table 1). At
randomization 74 % of patients were receiving the co-
formulated regimen consisting of TDF, FTC, and efavirenz
(i.e., Atripla). In the switch group versus the no-switch
group, participants had a mean duration of 6 versus 5 years
since HIV diagnosis, 4 versus 3 years since first ARV
therapy use, and 77 versus 80 % had asymptomatic disease,
respectively. HRQL as evaluated by the SF-36 PCS and
MCS was high on the baseline regimen in both groups
(switch group: mean [standard deviation {SD}] PCS 55.3
[5.9], MCS 50.0 [10.4]; no-switch group: PCS 56.0 [4.7],
MCS 51.7 [9.0]). On average, participants in both groups
had similar CES-D and STAI scores across visits that
reflected low levels of depressive and anxiety symptoms.
3.2 Descriptive Analysis of PRO Measures
A statistically significant difference was observed in the
prevalence of symptom bother for five HIV-SI items
(nightmares, vivid dreams, weird/intense dreams, muscle
aches/joint pain, and fevers/chills/sweats) at baseline
(Table 2). While the no-switch group tended to remain
steady over time and/or increase at week 4, a total of 12
symptoms in the switch group decreased significantly from
baseline to week 4. These improvements compared with
baseline remained significant at week 48 for eight symptoms
(nightmare, vivid dreams, weird/intense dreams,
dizzy/lightheadedness, nervous/anxious, difficulty sleeping,
diarrhea/loose bowels, and fever/chills/sweats). Importantly,
this descriptive analysis evaluated differences in prevalence
for each study visit in relation to baseline and did not control
for differences due to demographic and clinical factors.
Trends over time controlling for baseline differences for
these HIV symptoms are further discussed in relation to the
results of the regression and longitudinal analyses.
Patient-reported treatment adherence was C98 on the
100-point VAS across study visits in both treatment groups
(see Table 1 in the Electronic Supplementary Material
[ESM]). Treatment satisfaction was similar between groups
at baseline. At weeks 4 and 24, the mean HIVTSQc scores
were positive for both groups, indicating greater satisfac-
tion with treatment; however, the scores for the switch
group were statistically significantly higher than those for
the no-switch group (week 4: switch group mean [SD] 18.7
[11.6], no-switch group 13.4 [13.2]; week 24: switch group
mean [SD] 21.7 [10.2], no-switch group 15.1 [13.0]).
3.3 Associations between HIV-SI Bothersome
Symptoms and Treatment in Logistic
Regression Models and Longitudinal analyses
The elimination of potential covariates from models was
informed by item distributions and multicolinearity. The
final model included treatment group (no-switch vs.
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switch) as the independent variable and the following
covariates: age, sex, race (white vs. non-white), HIV-SI
symptom count at baseline, VACS Index score, years since
HIV diagnosis, years since first ARV therapy use, NNRTI
(non-EFV), serious mental illness, baseline CES-D score,
and baseline MCS and PCS scores. Table 2 in the ESM
present results that show that switching to STB was asso-
ciated with lower probabilities of experiencing 11 HIV
symptoms at one or more time points in adjusted logistic
regression models.
Table 1 Baseline characteristics
Switch group (N = 291) No-switch group (N = 143) p value
Male, n (%) 268 (92.1) 134 (93.7) 0.55
Age, mean years (SD) 42 (9.6) 40 (9.7) 0.008
Race, n (%) 0.45
White 231 (79.4) 109 (76.2)
Non-White 60 (20.6) 34 (23.1)
Ethnicity, n (%) 0.78
Hispanic or Latino 30 (10.3) 16 (11.2)
Serious mental illnessa 48 (16.5) 16 (11.2) 0.14
VACS Index Scoreb, mean (SD) 8.7 (10.4) 7.6 (9.3) 0.34
Asymptomatic, n (%) 225 (77.3) 115 (80.4) 0.46
CD4 cell count (cells per lL), mean (SD) 586 (210.3) 593 (224.6) 0.99
Years since HIV diagnosis, mean (SD) 6.0 (4.3) 5.0 (2.9) 0.16
Years since first antiretroviral therapy use, mean (SD) 4.0 (1.9) 3.0 (1.7) 0.55
On first antiretroviral therapy regimen at randomization, n (%) 263 (90.4) 130 (90.9) 0.86
NNRTI at randomization, n (%) 0.13
Efavirenz 232 (79.7) 106 (74.1)
Co-formulated efavirenz, emtricitabine, and tenofovir DF 222 (76.3) 100 (69.9)
Nevirapine 47 (16.2) 27 (18.9)
Rilpivirine 9 (3.1) 10 (7.0)
Co-formulated rilpivirine, emtricitabine, and tenofovir DF 7 (2.4) 9 (6.3)
Etravirine 3 (1.0) 0 (0.0)
HIV-SI symptom countc, mean (SD) 4.9 (5.2) 3.8 (4.6) 0.038
CES-D total depressive symptom scored, mean (SD) 9.8 (9.3) 8.9 (8.6) 0.34
STAI-State anxietye, mean (SD) 32.8 (10.6) 30.8 (9.2) 0.22
STAI-Trait anxietye, mean (SD) 33.8 (11.1) 32.6 (9.6) 0.51
SF-36 PCSf, mean (SD) 55.3 (5.9) 56.0 (4.7) 0.50
SF-36 MCSf, mean (SD) 50.0 (10.4) 51.7 (9.0) 0.19
For categorical data, p value was from the Cochran–Mantel–Haenszel (CMH) test (using the general association statistic). For continuous data,
p value was from the two-sided Wilcoxon rank sum test. P value comparing NNRTI at randomization compared the distribution of all four
NNRTIs (efavirenz, nevirapine, rilpivirine, and etravirine) and did not focus on individual NNRTIs
CES-D Center for Epidemiological Studies Depression, NNRTI non-nucleoside reverse transcriptase inhibitor, SD standard deviation, SF-36 MCS
Short Form 36 Mental Component Summary, SF-36 PCS Short Form 36 Physical Component Summary, STAI State Trait Anxiety Inventory,
VACS Veterans Aging Cohort Study
a Serious mental illness is defined as a medical history of at least one of the following diagnoses reported by the study investigator: major
depression, anxiety, schizophrenia, bipolar disorder, post-traumatic stress disorder, or other psychosis
b VACS Index is a score derived from the patient’s age, CD4 cell count, HIV-1 RNA level, hemoglobin value, platelet count, aspartate and
alanine transaminase levels, serum creatinine value, and a positive hepatitis C infection status at one specific time point
c The HIV-SI bothersome symptom count is a summation of the presence of the individual HIV-SI items and ranges from 0 to 26, with higher
counts indicating more bothersome symptoms
d The CES-D total score ranges from 0 to 60, with higher scores indicated greater depression severity
e Scores for both scales of the STAI range from 20 to 80, with higher scores indicating greater anxiety severity
f SF-36 PCS and MCS are scored from 0 to 100, with higher scores indicating better health
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The prevalence of bothersome symptoms over time was
evaluated using mixed-effects logistic models with the
same predictor list specified above. In all instances, the
BIC of the multivariate model showed a substantial
improvement in fit over the simple unadjusted model with
treatment only, suggesting that bothersome symptom
prevalence was associated with at least some of the pre-
dictors included in the model.
The adjusted longitudinal models revealed a statisti-
cally significant difference in the prevalence of several
symptoms between the switch and no-switch groups over
time. A complete table showing the coefficients, including
findings for main effects and time by treatment interac-
tions, is provided in Table 3 in the ESM. Table 3 cate-
gorizes groups of symptoms with similar patterns of
statistically significant results from the regression and
longitudinal analyses. Figures 1 and 2 plot the prevalence
of symptoms among the categorized groups at each data
collection time point and indicate the statistically signif-
icant Chi-squared test for difference between the switch
and no-switch groups. In Group 1, the prevalence of
nightmare, vivid dreams, weird/intense dreams,
dizzy/lightheadedness, fatigue/loss of energy, and pain/
numbness/tingling in the hands/feet were each signifi-
cantly lower in the switch group than in the no-switch
group at week 4 (and also at week 48 for nightmare, vivid
dreams, weird/intense dreams, dizzy/lightheaded, and
pain/numbness/tingling in hands and feet). Furthermore,
the switch group maintained its advantage over time, or
declined equally with the no-switch group in prevalence
Table 2 Frequency of HIV symptoms at baseline and weeks 4 and 48 in the ‘switch’ and ‘no-switch’ groups













Nightmare 21.7 13.0 9.1*** 15.7 7.9*** 13.4
Vivid dreams 26.9 15.9 14.9*** 22.0 12.8*** 20.2
Weird/intense dreams 26.6 15.9 14.9*** 20.5 11.3*** 16.8
Dizzy/lightheadedness 19.9 17.4 12.0** 20.5 12.8** 16.8
Fatigue/loss of energy 32.2 27.5 28.3 34.6 28.6 30.3
Pain/numbness/tingling in
hands/feet
20.3 14.5 14.9* 18.9 16.9 20.2
Nervous/anxious 30.1 22.5 19.6*** 26.8 21.1** 16.0
Drowsy 20.3 19.6 15.6 22.0 21.1 15.1
Difficulty sleeping 38.8 30.4 30.4** 33.1 28.6** 27.7
Diarrhea/loose bowels 25.9 21.0 18.1** 22.0 17.3** 17.6
Bloating/pain/gas in stomach 19.2 17.4 23.9 18.1 19.2 13.4
Trouble remembering 21.0 19.6 15.6* 19.7 19.2 17.6
Feeling off balance 11.5 9.4 9.8 12.6 9.4 9.2
Changes in body composition 23.1 23.9 17.0* 24.4 21.8 19.3
Problems with sex 26.9 21.7 23.2 19.7 22.9 20.2
Skin problems/rash/itching 21.3 15.9 18.1 22.0 24.1 15.1
Muscle aches/joint pain 20.3 12.3 17.4 17.3 22.6 17.6
Fevers/chills/sweats 15.0 8.0 8.7** 5.5 8.3* 9.2
Headaches 14.3 13.0 16.7 13.4 13.9 12.6
Hair loss/changes 11.9 10.9 6.2** 11.0 9.4 10.1
Nausea 9.8 5.1 12.3 8.7 6.8 8.4
Cough/trouble breathing 8.4 6.5 10.9 8.7 8.6 8.4
Loss of appetite/food taste 5.9 5.8 7.6 7.9 8.3 7.6
Unsteady walking 7.7 2.9 6.9 7.1 6.8 3.4
Weight loss/wasting 7.3 5.8 5.4 10.2 4.9 6.7
Vomiting 1.7 1.4 2.5 3.9 2.6 2.5
* p\ 0.05, ** p\ 0.01, *** p\ 0.001 McNemar test within group for change from baseline
 p\ 0.05,  p\ 0.01,  p\ 0.001 Chi-squared test between group differences
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as demonstrated in the longitudinal analyses for these
symptoms (Fig. 1). In Group 2, the prevalence of nervous/
anxious and drowsiness was significantly lower in the
switch group at week 4; however, the switch group lost its
advantage over time as indicated by the significant time-
by-treatment interaction from the longitudinal analyses
(Fig. 2). For Group 3, HIV symptoms (difficulty sleeping,
diarrhea/loose bowels, bloating/pain/gas in stomach), no
statistically significant differences in prevalence were
observed at the week 4 or 48 time points by treatment
group; however, the longitudinal analyses revealed that,
compared with baseline, the prevalence of these symp-
toms decreased over time and the decrease differed by
treatment group (Fig. 2). The prevalence of difficulty
sleeping and diarrhea/loose bowels was lower in the
switch group over time, while bloating/pain/gas in stom-
ach decreased in prevalence in the no-switch group. For
Group 4 (trouble remembering, feeling off balance, and
changes in body composition), the lower prevalence in the
switch group that was statistically significant at week 4
was not observed longitudinally from week 4 to week 48
(Fig. 2).









Description of longitudinal findings
Group 1: Bothersome symptoms with decreased prevalence at week 4 and maintained through week 48
Nightmare  4* 4 4 Decreased prevalence in both groups from week 4 to week 48, with
lower prevalence in switch group
Vivid dreams  4* 4* 4 Decreased prevalence in both groups from week 4 to week 48 with
lower prevalence in switch group
Weird/intense dreams  4 4 4 Switch group decreased prevalence maintained over study period
without any changes in prevalence from week 4 to week 48
Dizzy/lightheadedness 4* 4 4 Switch group decreased prevalence maintained over study period
without any changes in prevalence from week 4 to week 48
Fatigue/loss of energy 4 4 Switch group decreased prevalence maintained over study period
without any changes in prevalence from week 4 to week 48
Pain/numbness/
tinging in hands/feet
4 4 4 Switch group decreased prevalence maintained over study period
without any changes in prevalence from week 4 to week 48
Group 2: Bothersome symptoms with early decreases and longitudinal time by treatment interaction
Nervous/anxious 4 4 Switch group with fluctuating prevalence (week 48 lower than baseline);
no-switch group with decreased prevalence from week 4 to week 48
Drowsy 4 4 Switch group with fluctuating prevalence (week 48 similar to baseline);
no-switch group with decreased prevalence from week 4 to week 48
Group 3: Bothersome symptoms with differences in prevalence longitudinally
Difficulty Sleeping 4 Switch group decreased prevalence maintained over study period
without any changes in prevalence from week 4 to week 48
Diarrhea/loose bowels 4 Switch group decreased prevalence maintained over study period
without any changes in prevalence from week 4 to week 48
Bloating/pain/gas in
stomach
9 No-switch group decreased prevalence maintained from week 4 to week
48
Group 4: Bothersome symptoms with decreased prevalence only at week 4
Trouble remembering 4 No differences in prevalence observed between the groups from week 4
to week 48




4  No differences in prevalence observed between groups from week 4 to
week 48
* Also significant in unadjusted model
 Statistically significantly higher prevalence in the switch group
 Statistically significant time-by-treatment interaction
4 Statistically significant reduction for the switch group
9 Statistically significant reduction for the no-switch group
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Fig. 1 Group 1. p\ 0.05 statistically significant Chi-squared test between group differences
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Fig. 2 Groups 2, 3, and 4
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3.4 Associations between Health-Related Quality-
of-Life Outcomes (SF-36 Physical Component
and Mental Component Scores) and Treatment
in Linear Regression Models and Longitudinal
Analyses
HRQL was maintained in subjects who switched to STB
and was comparable to those who continued the NNRTI,
FTC, and TDF regimen. Treatment was not associated with
HRQL as assessed by the PCS or MCS at week 4 or week
48 in the unadjusted or adjusted linear multiple regression
analyses or in the longitudinal modeling of these outcomes
(see Table 4 in the ESM).
4 Discussion
In this study, the first prospective, randomized HIV switch
trial to use the modified HIV-SI to assess the symptom
experience of patients switching off an NNRTI, a switch to
STB was associated with better treatment satisfaction,
improvements in six patient-reported HIV symptoms that
were maintained over the 48-week study period compared
with continuation of an NNRTI with FTC and TDF, and no
differences or changes in HRQL. Statistical analyses
included cross-sectional regressions using data from two
key time points in the trial: week 4, the first follow-up visit
after switching to STB and the earliest opportunity to see a
potential treatment benefit; and week 48, a primary efficacy
outcome study visit. Mixed-effects longitudinal modeling
was also conducted in order to better understand whether
early reductions were maintained across the six follow-up
study visits.
Importantly, rather than evaluating the presence of HIV
symptoms, this secondary analysis identified those symp-
toms that bothered the patient and included questions that
assessed well-described side effects of efavirenz, including
abnormal dreams (vivid dreams, nightmare, weird/intense
dreams) and drowsiness (feeling drowsy, feeling off bal-
ance, unsteady walking). Abnormal dreams were asked
about in three different ways to capture the most specific
accurate interpretations of those symptoms given that
patients were completing a self-administered instrument
for data collection. The rationale for including three
questions on drowsiness was to further understand whether
patients were bothered by other effects on equilibrium and
balance beyond ‘dizziness’, as suggested by post-market-
ing reports of efavirenz [11].
Building on the descriptive analysis results—which
showed the switch group had a higher prevalence in five
HIV-SI items at baseline and significant reductions in eight
HIV symptoms at week 48—regression analyses revealed
that switching to STB from an NNRTI plus FTC/TDF
regimen was associated with decreases in the frequency of
11 HIV symptoms at week 4; however, those differences
were not always maintained over time, setting some
symptom experiences apart from others. The most clear
treatment benefits are for the six HIV symptoms catego-
rized as group 1: nightmare, vivid dreams, weird/intense
dreams, dizzy/lightheadedness, fatigue/loss of energy, and
pain/numbness/tingling in the hands/feet. Each of these
symptoms had a significantly lower prevalence in the
switch group than in the no-switch group at week 4, and
over time the switch group maintained its advantage or
declined equally with the no-switch group in terms of
prevalence. While symptom declines tended to taper off
toward the end of the follow-up period, the prevalence of
five of these symptoms—nightmare, vivid dreams, weird/
intense dreams, dizzy/lightheadedness, and pain/numbness/
tingling in the hands/feet—was significantly lower in the
switch group than in the no-switch group in the logistic
regression analysis conducted at week 48. The statistically
higher prevalence of nightmare, vivid dreams, and weird/
intense dreams in the switch group as compared with the
no-switch group at baseline should be considered in
interpreting the results, as there could be potential for bias.
This concern is most relevant to the baseline to week 4
change in prevalence: because the switch group was
starting from a higher prevalence rate at baseline, it had a
greater range of improvement to achieve.
Some of the symptoms with the strongest evidence of
decline—nightmare, vivid dreams, and weird/intense
dreams—are not only bothersome but costly. Simpson
et al. [25] looked at the incidence and cost of 11 adverse
events (rash, nausea or vomiting, diarrhea, dizziness,
headache, sleep-related symptoms, hepatotoxicity, lipid
disorders, depression, anxiety, and suicide or self-injury)
among NNRTI users and found sleep-related adverse
events to be the most expensive with regard to outpatient
services, with a mean cost per episode of $US6438 (in-
terquartile range 615–5882; median 1785). Further, the
overall mean healthcare cost of sleep-related symptoms
($US8307) was second to that of nausea and vomiting
($US12,833) [25].
In contrast to evidence of early sustained improvements
found for symptoms in group 1, the impact of treatment on
symptoms in groups 2–4 is not completely clear. For ner-
vous/anxious and drowsiness, statistically significant time-
by-treatment interactions, in addition to significant main
effects for treatment were present, indicating the switch
group lost its prevalence advantage over the no-switch
group over time. These results may be explained in part by
the fact that, at week 4, not only had the switch group
improved significantly, but the no-switch group worsened
substantively (statistically significant for drowsiness);
however, this trend did not continue longitudinally. For
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difficulty sleeping, diarrhea/loose bowels, and bloat-
ing/pain/gas in stomach (group 3), longitudinal modeling
showed statistically significant main effects for treatment,
indicating a difference in the prevalence trajectories of the
two groups, while no significant differences between
groups were observed at weeks 4 and 48. The lower
prevalence of difficulty sleeping in the longitudinal model
favored the switch group and was consistent with findings
for other sleep-related symptoms. The prevalence over time
of diarrhea/loose bowels was also lower in the switch
group, while the prevalence of bloating/pain/gas in the
stomach over time remained the same in the switch group
and was lower in the no-switch group. Given there was no
change in therapy for the no-switch group, it is somewhat
counterintuitive that there was a decrease in the prevalence
of bothersome bloating/pain/gas in the stomach for this
group. The difference in prevalence of group 4 symptoms
(trouble remembering, feeling off balance, and changes in
body composition), which significantly favored the switch
group, was isolated to week 4. That these symptoms are not
commonly described symptoms of any NNRTI weakens
the case for there being a clear treatment benefit.
While differences in the prevalence of some HIV
symptoms were observed between groups, there were 12
symptoms for which differences in the patterns of preva-
lence were not detected. In adjusted models, reductions
were essentially parallel over time for problems with sex,
skin problems/rash/itching, muscle aches/joint pain, fevers/
chills/sweats, headaches, hair loss or changes, nausea,
coughing/trouble breathing, loss of appetite/food taste,
unsteady walking, weight loss/wasting, and vomiting. The
statistically significant associations found among multiple
covariates with these bothersome symptoms (e.g., race,
baseline VACS Index, years since HIV diagnosis, and
years since first ARV therapy) highlights other important
associations to consider.
HRQL outcomes (SF-36 MCS and PCS scores) were
similar for participants who switched to STB and for those
who remained on their existing NNRTI-containing regimen.
Patients in both groups maintained their mental and physical
health functioning throughout the treatment study. These
findings are consistent with a 2014 review [26] that found
that, of ten trials including patients on NNRTI-containing
regimens that measured patient-reported HRQL, half
showed no significant difference on any measured HRQL
domain—a trend that was particularly apparent when less
sensitive tools evaluating general HRQL were used.
A notable strength of the present study is the use of PRO
tools, providing insight into patient-reported symptoms that
may be under-reported by clinicians [2]. The use of lon-
gitudinal modeling of patient-reported data contributes a
richer understanding of the prevalence of HIV symptoms
over time after switching ARV therapy (i.e., relation to
treatment) and, to our knowledge, has not been conducted
in prior HIV clinical trials. The categorization of results
based on cross-sectional regression modeling and longitu-
dinal modeling provides a method of interpreting findings
at key time points and over time, which may facilitate a
better understanding of symptom patterns and lend insight
into how HIV symptoms cluster, though this should be
studied further in additional patient populations.
Important limitations of this study should be noted. The
majority of the study population was male and White, and
these findings may not be generalizable to women and
patients of non-White race. Further, the inclusion criteria
stipulated that all patients have viral loads at baseline that
were undetectable on therapy, yielding a highly treatment-
adherent population. Thus, study results are more gener-
alizable to a virologically suppressed patient population
than a treatment-naı¨ve patient population. There was a
significant higher prevalence in the switch group for five
HIV-SI items at baseline, suggesting balance was not
achieved in randomization. In addition, it is possible that
study findings may be confounded by knowledge of treat-
ment assignment. The open-label design may have affected
the changes in HIV symptoms found at week 4 between
groups; perhaps patients in the no-switch group noticed
their symptoms more acutely and those in the switch group
were more attuned to symptom improvements. At subse-
quent visits, these changes were less dramatic. Use of an
alternative HRQL measure, rather than the SF-36, designed
specifically for the HIV patient population would yield
more meaningful HRQL data. Finally, interpretation of the
conducted analyses relied on statistical significance, rigid
criteria to apply to an exploratory analysis.
5 Conclusion
This study provides evidence that switching virologically
suppressed patients to STB from an NNRTI plus FTC/TDF
regimen was associated with a decreased prevalence in 11
symptoms as early as 4 weeks after the switch. Enduring
benefits at week 48 were observed for nightmare, vivid
dreams, weird/intense dreams, dizzy/lightheadedness, fati-
gue/loss of energy, and pain/numbness in the hands/feet.
As people with HIV receiving ART now have life
expectancies approaching those without HIV, it is impor-
tant to identify and take steps to limit those symptoms that
interfere with general health and well-being. Future
research in real-world clinical settings is needed to better
understand how switching to STB may impact symptoms
and other PROs.
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